LALPATHLAB2021-04-012021-06-30in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2021-04-012021-06-30in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2021-04-012021-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares LALPATHLAB 2021-04-01 2022-03-31 2021-07-23 INR Millions First quarter Single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2021-04-01 2021-06-30 Unaudited Consolidated 6066000000.00 141000000.00 6207000000.00 1451000000.00 0.00 0.00 864000000.00 46000000.00 192000000.00 1861000000.00 4414000000.00 1793000000.00 0.00 1793000000.00 521000000.00 -65000000.00 456000000.00 0.00 1337000000.00 0.00 0.00 0.00 0.00 1337000000.00 -1000000.00 1336000000.00 1312000000.00 25000000.00 1311000000.00 25000000.00 833000000.00 10 15.87 15.84 0.00 0.00 15.87 15.84 i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 July, 2021. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter ended June 30, 2021 and they have expressed an unmodified conclusion on the aforesaid results. ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. iv. Figures for the quarter ended 31 March, 2021 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2020, which were subjected to limited review. v. The Board of Directors of the Parent Company have approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 30 July, 2021. vi. The results of quarter ended June 30, 2021 are not strictly comparable with the results of the previous quarter and corresponding previous quarter, due to resurgent wave of COVID -19 in quarter ended June 30, 2021 and nationwide lockdown in the corresponding previous quarter. vii. The Board of Directors of the Parent Company and one of the subsidiary company's APL Institute of Clinical Laboratory & Research Private Limited ( APL ) in their respective board meetings held on 3 February, 2020 had approved the “Scheme of Amalgamation” of APL with the Parent Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme the undertaking of APL shall stand transferred to and vested in the Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders, National Company Law Tribunal and other statutory approvals. viii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. ix. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Group is in the process of assessing the impact of the relevant provisions. Fees to collection centers/channel partners 921000000.00 Other expenses 940000000.00